Buy MK-2866 (Ostarine) 30mg x30 Capsules

MK-2866 (Ostarine, Enobosarm) is the original and most extensively studied selective androgen receptor modulator. It was developed by GTx to address muscle wasting and osteoporosis, advancing to Phase III clinical trials. At research doses (10-30mg/day), it selectively activates androgen receptors in muscle and bone tissue without the virilizing effects of anabolic steroids.

▸Clinical Trial Data

Phase II trials demonstrated significant lean mass preservation in cancer patients experiencing cachexia at 3mg/day — far below typical fitness dosing. Phase III (POWER 1 and 2 trials) for cancer cachexia enrolled 650+ patients, representing the most clinical data of any SARM compound. Lean mass gains of 1.5-3kg over 12 weeks at 10-25mg/day are consistently reported in fitness research applications.

▸Selectivity and Hormonal Profile

Ostarine preferentially binds androgen receptors in muscle and bone versus prostate and reproductive tissue, reducing androgenic side effects. At 30mg/day, mild testosterone suppression occurs — typically reversible within 4-6 weeks of discontinuation. PCT is generally recommended at doses above 15mg/day for cycles longer than 4 weeks.

▸Bone Density Benefits

A secondary finding in cancer trial data: Ostarine improved bone mineral density alongside lean mass preservation. This dual muscle + bone anabolic effect makes it particularly relevant for older users with both sarcopenia and osteoporosis risk.